人工智能在膀胱癌诊疗中的价值
The Value of Artificial Intelligence in the Diagnosis and Treatment of Bladder Cancer
DOI: 10.12677/acm.2025.15123491, PDF,   
作者: 吴 冰, 毛嘉颖：绍兴文理学院医学院，浙江 绍兴；赵振华*：绍兴市人民医院(绍兴文理学院附属第一医院)放射科，浙江 绍兴
关键词: 膀胱癌；影像组学；深度学习；Bladder Cancer； Radiomics； Deep Learning
摘要: 膀胱癌是全球范围内发病率居第二位的泌尿系统恶性肿瘤，也是导致男性患者死亡的主要癌种之一。早期病变识别与精准的病理分级分期对于改善患者预后具有重要意义。近年来，人工智能技术在医学影像分析中显示出显著优势，能够提取人类视觉难以辨识的图像特征，从而在膀胱癌诊断与治疗领域展现出重要潜力。本文将从人工智能在膀胱癌诊疗研究中的最新进展系统综述。
Abstract: Bladder cancer ranks as the second most common malignancy of the urinary system worldwide and is one of the leading causes of cancer-related death among males. Early lesion identification and accurate pathological grading and staging are essential for improving patient prognosis. In recent years, artificial intelligence has demonstrated considerable potential in medical image analysis by extracting features imperceptible to the human eye, indicating its promising role in the diagnosis and treatment of bladder cancer. This article systematically reviews recent advances in the application of artificial intelligence in bladder cancer research.
文章引用：吴冰, 毛嘉颖, 赵振华. 人工智能在膀胱癌诊疗中的价值[J]. 临床医学进展, 2025, 15(12): 961-966. https://doi.org/10.12677/acm.2025.15123491

参考文献

[1] Bray, F., Laversanne, M., Sung, H., Ferlay, J., Siegel, R.L., Soerjomataram, I., et al. (2024) Global Cancer Statistics 2022: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA: A Cancer Journal for Clinicians, 74, 229-263. [Google Scholar] [CrossRef] [PubMed]
[2] 中国肿瘤医院泌尿肿瘤协作组. 膀胱癌保膀胱治疗多学科诊治协作专家共识(2024版) [J]. 中华肿瘤杂志, 2024, 46(12): 1136-1155.
[3] Chen, X., Wahafu, W., Shen, Y., Fan, J. and Yao, X. (2024) CACA Guidelines for Holistic Integrative Management of Urothelial Carcinoma. Holistic Integrative Oncology, 3, Article No. 9. [Google Scholar] [CrossRef] 
[4] Alfred Witjes, J., Max Bruins, H., Carrión, A., Cathomas, R., Compérat, E., Efstathiou, J.A., et al. (2024) European Association of Urology Guidelines on Muscle-Invasive and Metastatic Bladder Cancer: Summary of the 2023 Guidelines. European Urology, 85, 17-31. [Google Scholar] [CrossRef] [PubMed]
[5] Arcangeli, G., Strigari, L. and Arcangeli, S. (2015) Radical Cystectomy versus Organ-Sparing Trimodality Treatment in Muscle-Invasive Bladder Cancer: A Systematic Review of Clinical Trials. Critical Reviews in Oncology/Hematology, 95, 387-396. [Google Scholar] [CrossRef] [PubMed]
[6] Patel, V.G., Oh, W.K. and Galsky, M.D. (2020) Treatment of Muscle‐Invasive and Advanced Bladder Cancer in 2020. CA: A Cancer Journal for Clinicians, 70, 404-423. [Google Scholar] [CrossRef] [PubMed]
[7] Mayerhoefer, M.E., Materka, A., Langs, G., Häggström, I., Szczypiński, P., Gibbs, P., et al. (2020) Introduction to Radiomics. Journal of Nuclear Medicine, 61, 488-495. [Google Scholar] [CrossRef] [PubMed]
[8] Wu, S., Hong, G., Xu, A., Zeng, H., Chen, X., Wang, Y., et al. (2023) Artificial Intelligence-Based Model for Lymph Node Metastases Detection on Whole Slide Images in Bladder Cancer: A Retrospective, Multicentre, Diagnostic Study. The Lancet Oncology, 24, 360-370. [Google Scholar] [CrossRef] [PubMed]
[9] Du, Y., Li, H., Sui, Y., Tao, Y., Cao, J., Jiang, X., et al. (2025) Habitat‐Based Radiomic Model for Predicting Muscle Invasion in Bladder Cancer: A Multi‐Center Study Using Enhanced‐CT and Machine Learning. Medical Physics, 52, e18021. [Google Scholar] [CrossRef] [PubMed]
[10] Song, H., Yang, S., Yu, B., Li, N., Huang, Y., Sun, R., et al. (2023) CT-Based Deep Learning Radiomics Nomogram for the Prediction of Pathological Grade in Bladder Cancer: A Multicenter Study. Cancer Imaging, 23, Article No. 89. [Google Scholar] [CrossRef] [PubMed]
[11] Lisson, C.G., Gallee, L., Müller, K., Manoj, S., Stöckl, H., Zengerling, F., et al. (2025) Machine Learning-Based Radiomics for Bladder Cancer Staging: Evaluating the Role of Imaging Timing in Differentiating T2 from T3 Disease. Frontiers in Oncology, 15, Article 1591742. [Google Scholar] [CrossRef] 
[12] Qureshi, T.A., Chen, X., Xie, Y., Murakami, K., Sakatani, T., Kita, Y., et al. (2023) MRI/RNA-Seq-Based Radiogenomics and Artificial Intelligence for More Accurate Staging of Muscle-Invasive Bladder Cancer. International Journal of Molecular Sciences, 25, Article 88. [Google Scholar] [CrossRef] [PubMed]
[13] de Angelis, M., Pellegrino, F., Scilipoti, P., Shariat, S.F., Fujii, Y., Roupret, M., et al. (2025) PD37-06 Real-World Adoption and Impact of Neoadjuvant Chemotherapy on Survival Outcomes in Bladder Cancer: A 20-Year Follow-Up Multi-Center Study. Journal of Urology, 213, e1338. [Google Scholar] [CrossRef] 
[14] Contieri, R., Saita, A., Paciotti, M., Uleri, A., Avolio, P.P., Fasulo, V., et al. (2025) PD12-04 Evaluating Neoadjuvant Intravesical Mitomycin C in NMIBC: A Phase III Randomized Clinical Trial. Journal of Urology, 213, e388. [Google Scholar] [CrossRef] 
[15] Chamie, K., Ballon-Landa, E., Daskivich, T.J., Bassett, J.C., Lai, J., Hanley, J.M., et al. (2015) Treatment and Survival in Patients with Recurrent High-Risk Non-Muscle-Invasive Bladder Cancer. Urologic Oncology: Seminars and Original Investigations, 33, 20.e9-20.e17. [Google Scholar] [CrossRef] [PubMed]
[16] Meng, L., Khorasanchi, A. and Jain, R. (2025) Advancing Bladder Cancer Management: The Role of Neoadjuvant and Adjuvant Therapies and Biomarkers in Muscle Invasive Bladder Cancer. Current Treatment Options in Oncology, 26, 929-942. [Google Scholar] [CrossRef] 
[17] Yu, J., Wu, S., Li, R., Jiang, Y., Zheng, J., Li, Z., et al. (2023) Novel ADCs and Combination Therapy in Urothelial Carcinoma: Latest Updates from the 2023 ASCO-GU Cancers Symposium. Journal of Hematology & Oncology, 16, Article No. 85. [Google Scholar] [CrossRef] [PubMed]
[18] Hong, X., Chen, X., Wang, H., Xu, Q., Xiao, K., Zhang, Y., et al. (2023) A HER2‐Targeted Antibody‐Drug Conjugate, RC48‐ADC, Exerted Promising Antitumor Efficacy and Safety with Intravesical Instillation in Preclinical Models of Bladder Cancer. Advanced Science, 10, e2302377. [Google Scholar] [CrossRef] [PubMed]
[19] Liu, Z., Xing, L., Zhu, Y., Shi, P. and Deng, G. (2022) Association between TOP2A, RRM1, HER2, ERCC1 Expression and Response to Chemotherapy in Patients with Non-Muscle Invasive Bladder Cancer. Heliyon, 8, e09643. [Google Scholar] [CrossRef] [PubMed]
[20] Park, K.J., Lee, J., Yoon, S., Heo, C., Park, B.W. and Kim, J.K. (2020) Radiomics-Based Prediction Model for Outcomes of PD-1/PD-L1 Immunotherapy in Metastatic Urothelial Carcinoma. European Radiology, 30, 5392-5403. [Google Scholar] [CrossRef] [PubMed]
[21] Bai, Z., Osman, M., Brendel, M., Tangen, C.M., Flaig, T.W., Thompson, I.M., et al. (2025) Predicting Response to Neoadjuvant Chemotherapy in Muscle-Invasive Bladder Cancer via Interpretable Multimodal Deep Learning. npj Digital Medicine, 8, Article No. 174. [Google Scholar] [CrossRef] [PubMed]
[22] Patel, A., Garcia, L.F., Mannella, V., Gammon, L., Borg, T., Maffucci, T., et al. (2020) Targeting P63 Upregulation Abrogates Resistance to MAPK Inhibitors in Melanoma. Cancer Research, 80, 2676-2688. [Google Scholar] [CrossRef] [PubMed]
[23] Wang, B., Gong, Z., Su, P., Zhen, G., Zeng, T. and Ye, Y. (2025) Multi-Machine Learning Model Based on Radiomics Features to Predict Prognosis of Muscle-Invasive Bladder Cancer. BMC Cancer, 25, Article No. 1116. [Google Scholar] [CrossRef] [PubMed]
[24] Han, X., Guan, J., Guo, L., Jiao, Q., Wang, K., Hou, F., et al. (2025) A CT-Based Interpretable Deep Learning Signature for Predicting PD-L1 Expression in Bladder Cancer: A Two-Center Study. Cancer Imaging, 25, Article No. 27. [Google Scholar] [CrossRef] [PubMed]
[25] Cao, Y., Zhu, H., Li, Z., Liu, C. and Ye, J. (2024) CT Image-Based Radiomic Analysis for Detecting PD-L1 Expression Status in Bladder Cancer Patients. Academic Radiology, 31, 3678-3687. [Google Scholar] [CrossRef] [PubMed]
[26] Yu, R., Cai, L., Gong, Y., Sun, X., Li, K., Cao, Q., et al. (2024) MRI‐Based Machine Learning Radiomics for Preoperative Assessment of Human Epidermal Growth Factor Receptor 2 Status in Urothelial Bladder Carcinoma. Journal of Magnetic Resonance Imaging, 60, 2694-2704. [Google Scholar] [CrossRef] [PubMed]
[27] Peng, J., Tang, Z., Li, T., Pan, X., Feng, L. and Long, L. (2024) Contrast-Enhanced Computed Tomography-Based Radiomics Nomogram for Predicting HER2 Status in Urothelial Bladder Carcinoma. Frontiers in Oncology, 14, Article 1427122. [Google Scholar] [CrossRef] [PubMed]
[28] Jiao, P., Yang, R., Liu, Y., Fu, S., Weng, X., Chen, Z., et al. (2024) Deep Learning-Based Computed Tomography Urography Image Analysis for Prediction of HER2 Status in Bladder Cancer. Journal of Cancer, 15, 6336-6344. [Google Scholar] [CrossRef] [PubMed]
[29] Arita, Y., Kwee, T.C., Akin, O., Shigeta, K., Paudyal, R., Roest, C., et al. (2025) Multiparametric MRI and Artificial Intelligence in Predicting and Monitoring Treatment Response in Bladder Cancer. Insights into Imaging, 16, Article No. 7. [Google Scholar] [CrossRef] [PubMed]
[30] Kocak, B., Baessler, B., Bakas, S., Cuocolo, R., Fedorov, A., Maier-Hein, L., et al. (2023) Checklist for Evaluation of Radiomics Research (CLEAR): A Step-by-Step Reporting Guideline for Authors and Reviewers Endorsed by ESR and EuSoMII. Insights into Imaging, 14, Article No. 75. [Google Scholar] [CrossRef] [PubMed]
[31] Whybra, P., Zwanenburg, A., Andrearczyk, V., Schaer, R., Apte, A.P., Ayotte, A., et al. (2024) The Image Biomarker Standardization Initiative: Standardized Convolutional Filters for Reproducible Radiomics and Enhanced Clinical Insights. Radiology, 310, e231319. [Google Scholar] [CrossRef] [PubMed]

为你推荐